HomeANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
$0.00020
Pre-market:(99.50%)-0.00020
$0.00
Sarado: Nob 29, 8:43:11 AM GMT-5 · USD · OTCMKTS · Disclaimer
Nakaraang pagsara
$0.00020
Market cap
5.24K USD
Average na Volume
11.64K
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | 2017info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 7.94M | -28.30% |
Net na kita | -26.87M | 51.60% |
Net profit margin | — | — |
Kita sa bawat share | -3.80 | 70.53% |
EBITDA | -36.15M | 36.48% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | 2017info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.20M | -89.46% |
Kabuuang asset | 3.67M | -84.35% |
Kabuuang sagutin | 9.17M | -13.70% |
Kabuuang equity | -5.50M | — |
Natitirang share | 23.40M | — |
Presyo para makapag-book | -0.00 | — |
Return on assets | -167.77% | — |
Return on capital | -619.42% | — |
Cash Flow
Net change in cash
| (USD) | 2017info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -26.87M | 51.60% |
Cash mula sa mga operasyon | -36.90M | 24.57% |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | 18.25M | -22.58% |
Net change in cash | -18.65M | 28.58% |
Malayang cash flow | -23.15M | 18.17% |
Tungkol
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Itinatag
2004
Headquarters
Website
Mga Empleyado
21
